Answers are grounded in this paper and cite their sources.
Shows improved immune balance and reduced autoantibodies in Hashimoto's thyroiditis patients, suggesting potential therapeutic effects.
目的 探讨宁瘿方通过调控效应性T细胞(Teff)与调节性T细胞(Treg)亚群平衡改善桥本甲状腺炎(HT)免疫损伤的作用机制。 方法 采用前瞻性、随机、开放式、阳性对照的单中心临床研究设计,纳入132例肝郁脾虚型HT患者,按1∶1随机分为试验组(宁瘿方,n=60)和对照组(硒酵母片,n=63),疗程12周。通过流式细胞术检测外周血CD4⁺T细胞亚群(Th1、Th17、Th1-Th17、总Treg、初始Treg、活化Treg),电化学发光法检测甲状腺抗体(TPOAb、TgAb)及功能指标(TSH、FT₄),酶联免疫吸附法检测血清炎症因子(IFN-γ、IL-6),并结合中医证候积分评估疗效。 结果 治疗后,试验组TPOAb从428.35(250.10,683.79)IU/mL降至302.22(140.50,423.03)IU/mL,TgAb从131.71(68.46,328.91)IU/mL降至80.45(28.19,164.31)IU/mL(均P<0.05),显著优于对照组。试验组促炎亚群Th1、Th17百分比及绝对计数显著降低(P<0.05),调节亚群总Treg和活化Treg显著升高(P<0.05)。与治疗前比较,治疗后试验组Th17%下降幅度为18.55%,总Treg%上升幅度为28.42%,活化Treg%上升幅度300.00%。TPOAb与Th17%呈正相关(r=0.457,P<0.001),与活化Treg%呈负相关(r=-0.49,P<0.001)。试验组IFN-γ(6.96±5.90) pg/mL降至(3.46±2.27) pg/mL和IL-6(6.60±6.89)pg/mL降至(4.03±3.12)pg/mL水平显著下降(均P<0.05),中医证候积分由(20.25±4.19)降至(11.30±3.29)(P<0.05),总有效率达85.00%(对照组39.68%,P<0.05)。两组不良反应率无统计学差异(3.17% vs 5.00%,P>0.05)。 结论 宁瘿方可显著降低HT患者甲状腺自身抗体水平,抑制促炎T细胞亚群,上调活化Treg比例,改善免疫失衡及临床症状,其机制可能与调控Teff/Treg亚群平衡相关。
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: